Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- AI Summary
- About
QSAM 
Qsam Biosciences Inc (QSAM)
- BUY Advisory
- Profitable SELL
- Loss-Inducing SELL
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
05/02/2024: QSAM (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
Analysis of Past Performance
Type Stock | Historic Profit -81.06% | Avg. Invested days 22 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 05/02/2024 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 36.90M USD | Price to earnings Ratio - | 1Y Target Price - |
Price to earnings Ratio - | 1Y Target Price - | ||
Volume (30-day avg) 11761 | Beta 1.81 | 52 Weeks Range 4.00 - 8.49 | Updated Date 05/3/2024 |
52 Weeks Range 4.00 - 8.49 | Updated Date 05/3/2024 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.69 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -238.09% | Return on Equity (TTM) -3377.07% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 36027704 | Price to Sales(TTM) 1.71 |
Enterprise Value 36027704 | Price to Sales(TTM) 1.71 | ||
Enterprise Value to Revenue 18.26 | Enterprise Value to EBITDA -8.02 | Shares Outstanding 4445470 | Shares Floating 2065365 |
Shares Outstanding 4445470 | Shares Floating 2065365 | ||
Percent Insiders 52.36 | Percent Institutions - |
About NVIDIA Corporation
Exchange NASDAQ | Headquaters Austin, TX, United States | ||
IPO Launch date 2015-12-11 | Co-Founder, CEO & Director Mr. Douglas R. Baum | ||
Sector Healthcare | Industry Biotechnology | Full time employees 4 | Website https://qsambio.com |
Full time employees 4 | Website https://qsambio.com | ||
QSAM Biosciences, Inc. engages in developing various nuclear medicines for the treatment of cancer. The company is involved in the development of CycloSam (Samaium-153 DOTMP), a clinical-stage bone targeting radiopharmaceutical. It has a license agreement with IGL Pharma, Inc. The company was formerly known as Q2Earth, Inc. and changed its name to QSAM Biosciences, Inc. in September 2020. QSAM Biosciences, Inc. was incorporated in 2004 and is headquartered in Austin, Texas.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.